Mobile

An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-scalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in S...

Update Il y a 4 ans
Reference: EUCTR2007-006170-28

An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-scalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial seizures

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective is to evaluate the safety and tolerability of perampanel (up to12mg/day) given as adjunctive treatment in subjects with refractory partial seizures

Inclusion criteria

  • Epilepsy: refractory partial seizures with or without secondary generalisation

Links